The content on this site is intended for healthcare professionals only
Dr Gil Morgan from OncoAlert gives his oncology highlights from social media for the week of September 22-28th, 2023.
He begins by inviting colleagues to the 'Multidisciplinary Perspectives in Breast Cancer' conference taking place on October 6th.
Dr Morgan then highlighted the results of the KEYNOTE-A39/EV-302 trial, which showed that patients with previously untreated locally advanced or metastatic urothelial cancer met dual primary endpoints of overall survival and progression-free survival.
He also mentioned the CheckMate-77T trial, which demonstrated that a neoadjuvant regimen of Opdivo and chemotherapy followed by adjuvant Opdivo significantly improved event-free survival in patients with resectable non-small cell lung cancer.
Finally, Dr Morgan talked about the European Association of Nuclear Medicine Focus 5, where a panel of experts in prostate cancer imaging and treatment are working to reach a consensus on important issues such as the utilisation of PSMA PET imaging and other cutting-edge imaging techniques.
Follow Dr Morgan on twitter: @OncoAlert
Follow ecancer on twitter: @ecancer
Prostate cancer
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
Adjuvant radiotherapy has no benefit following radical prostatectomy
Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC
The Southeast Asian Breast Cancer Symposium; background, aims and successes
OncoAlert Round Up for August 4th - 10th, 2023
TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer
TARGIT-E: Intraoperative Radiotherapy (IORT) in elderly patients with small breast cancer
The use of IORT at Universitätsmedizin Mannheim hospital
